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To combat the early morning mortality associated with the pathophysiological dis-
eases of myocardial infarction and bronchial asthma, therapeutically active concentra-
tions of the drug are required in the early morning hours just prior to awakening (1).
This cannot be achieved with the conventional controlled-release formulations with zero
order kinetics. Therefore, the treatment should preferentially involve formulations that
release drugs rapidly after a defined delay period (2). Delayed-release systems mimic
the circadian rhythm of the disease by releasing the drug at the appropriate time when
the dosage forms come in contact with gastrointestinal fluids (3).
Delayed-release formulations generally have a rapidly disintegrating tablet core en-
compassed by a barrier layer formed by press-coating, polymer coating or a combina-
tion of both (4). Compared to polymer coating, the press-coating technique has the ad-
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of press-coated tablets with the outer layer of PEG 6000/
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and then pH 6.8 buffer solution was examined. Morpho-
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vantage of being used without solvents and requiring a relatively short manufacturing
process. Composition of the barrier layer controls the mechanism of effecting the lag ti-
me. Polymer blends could be a solution for creating a new composition, exhibiting the
appropriate flexibility for the adjustment of drug release delay (5, 6).
Salbutamol sulfate (STS) is one of the most widely used drugs for the treatment of
bronchial asthma, chronic bronchitis and emphysema (7). Treating diseases such as asth-
ma, with immediate-release dosage forms may not be effective if the disease is more pro-
nounced early in the morning. There is a need for a specially designed drug delivery
system that could maintain STS concentration at the therapeutic level for some time. STS
falls under Class I (high solubility-high permeability) drug according to the Biopharma-
ceutical Classification System and is absorbed throughout the gastrointestinal tract (8,
9).
In our previous study, we investigated the optimized formulation of a press-coated
tablet of salbutamol sulfate using polyethylene glycol 6000 (PEG 6000)-Eudragit S100
dispersion blends in the outer shell and evaluated its pharmacokinetic behavior in
beagle dogs (10). The objective of the present work was to investigate the morphological
change of the press-coated tablet during dissolution in in vitro and in vivo gamma scin-
tigraphic studies carried out on healthy men.
EXPERIMENTAL
Materials
Salbutamol sulfate was obtained from YaBang Co. Ltd. (Changzhou, China). So-
dium carboxymethyl starch (CMS-Na; DMV, Veghel, The Netherlands), low-substituted
hydroxypropyl cellulose (L-HPC, Shin-Etsu Company, Tokyo, Japan), lactose (BoDi Co.
Ltd., Tianjin, China), polyvinylpyrrolidone (PVP, Fengli Jingqiu Commerce & Trade Co.
Ltd., Tianjin, China), and magnesium stearate (BoDi Co. Ltd., Tianjin, China) were used
for the preparation of core tablets. PEG 6000 (Kermel Chemical Reagents Development
Centre, Tianjin, China) and Eudragit S100 (supplied as a gift by Degussa Co. Ltd. Shang-
hai Branch, China) were used for the outer shell of timed-release press-coated tablets.
Technetium-99m-diethylentriamine pentaacetic acid (99mTc-DTPA) was obtained from
the Department of Nuclear Medicine of the Shenyang General Hospital of Military Area
Command (Shenyang, China). All other chemicals and solvents were of standard phar-
maceutical grade.
Preparation of press-coated salbutamol sulfate tablets
A wet granulation method was applied to prepare granules for the core tablet. STS
core tablets were compression-coated with 150 mg PEG 6000-Eudragit S100 polymer
blends in a 2:1 m/m ratio prepared by the fusion method. Each core tablet consisted of 9.6
mg STS, 10 mg CMS-Na, 20 mg L-HPC and 20 mg lactose. The mixture was wetted with
3 % (m/V) polyvinylpyrrolidone ethanol solution as binder. The wetted mass was forced
through a 920 mm screen. The granules were dried at 50 °C and then sized by passing
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through a 1060 mm screen. Next, 0.5 % magnesium stearate, as lubricant based on total
mass, was added to the granules and mixed for 5 minutes so that the particle surface
was evenly coated by the lubricant. The granules were compressed at a compression force
of 4 kg mm–2 using a single punch tablet machine equipped with a concave punch 6 mm
in diameter (Jingcheng Machine Manufacture Co. Ltd., Shandong, China). The coating
layer was made of PEG 6000-Eudragit S100 polymer blends in a 2:1 (m/m) ratio. The re-
quired amount of polymer mixture was heated in a stainless steel vessel at 95–99 °C, fol-
lowed by stirring until homogeneous. It was then allowed to cool to room temperature
and kept in the refrigerator at 0–4 °C for two hours. After that, the mass was ground into
a very fine powder prior to use and 0.5 % magnesium stearate, as lubricant based on total
mass, was added. Press-coated tablets were prepared as follows: one half of the mixed
powder was filled into the die, and a core tablet was placed in the center of the polymer.
Then, the remaining half was filled in the die, and the entire content was compressed.
The coating material was compressed around the core tablet applying a force of 3 kg
mm–2 with 9.0 mm round concave punches using a single-punch tablet machine.
Preparation of radiolabelled tablets for the scintigraphy study
The core tablet (average mass 50 mg) for the in vivo scintigraphic study consisted of
9.6 mg STS, 10 mg CMS-Na, 20 mg L-HPC and 20 mg lactose. 99mTc-DTPA was selected
to radio label the tablets because of its short half-life of 6 h and very low electron emis-
sion. Lactose was used as filler and 5 mCi 99mTc-DTPA was adsorbed on it. Core tablets
containing 99mTc-DTPA were prepared by radiolabelling DTPA with a sodium pertech-
netate solution. Lactose was dissolved in this solution, evaporated to dryness. The ra-
dio-labeled core tablets were then press-coated using the preparation method described
above.
In vitro drug release studies
The dissolution study was performed according to the third method (paddle type)
described in part II of Pharmacopoeia of China (2010), using a paddle apparatus at 100
rpm. Dissolution media consisted of 100 mL of 0.1 mol L–1 HCl for the first 2 h and pH
6.8 phosphate buffers for the following 7 h at 37 ± 0.5 °C. Samples of 5 mL were with-
drawn at specified time intervals and filtered (0.45 mm). STS concentrations in sample
solutions were analyzed at 276 nm for STS using a UV9100 spectrophotometer (Rili Ana-
lytical Instrument Co. Ltd., Beijing, China). An equivalent volume of temperature-equili-
brated dissolution medium was replaced into the dissolution vessel following the remo-
val of each sample. Data represent the mean values of at least six separate experiments.
Photographic study
At predetermined time intervals (2, 3, 4 and 5 h), press-coated tablets were carefully
removed from the dissolution apparatus and images of the press-coated tablets were ob-
tained using a digital camera (Canon A590, Japan). When the press-coated tablets were
partly eroded after 6 h, images were taken in the dissolution media.
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In vivo gamma scintigraphic study
For delayed-release systems, gamma scintigraphy is a well established and useful
tool to monitor the dosage form location within the GI tract and assess its in vivo perfor-
mance (11). Visual tracking of dosage forms is of great importance if the performance of
the barrier layer depends upon its location within the GI tract. Two healthy males, 21
and 24 years old, 1.74 and 1.76 m tall and weighing 60 and 62 kg, respectively, partici-
pated in the study as volunteers. They were non-alcoholics, non-smokers, without a his-
tory of gastro-intestinal disorders and were not taking any regular medication. The pur-
pose of the study was fully explained and they had given their informed consent in
writing. The study was approved by the Independent Ethics Committee of the General
Hospital of Shenyang Military Command and was in full compliance with the principles
of the Good Clinical Practice guidelines.
After overnight fasting, the volunteers were given breakfast consisting of eggs,
bread and milk. Three hours later, they were given 200 mL of water to which 20 mCi
99mTcO4– had been added for the purpose of outlining the gastrointestinal tract. Radio-
-labeled tablets were then administered to volunteers 1 and 2. Gamma images were re-
corded using an online computer system (Millennium VG hawk-eye, USA) and static
10-s anterior images were acquired at hourly intervals. Gastrointestinal transit of the do-
sage forms was monitored and their break-up time was assessed.
RESULTS AND DISCUSSION
In vitro drug release of press-coated STS tablets
Fig. 1 shows the results of the salbutamol sulfate release from a press-coated tablet.
A very small amount of drug was released over the initial period in acidic to weakly
acidic medium. However, with an increase of pH, hydration and swelling of the PEG
6000/Eudragit S100 blends resulted in the rupture of the coating layer, followed by drug
release. In this study, 4 h lag time of release was calculated from the intersection of the
linear portion of release with the x-axis representing the time scale. As the drug release
behavior shows, the release of STS was less than 5 % before 3 h and was completed after
8 h in a pH 6.8 phosphate buffer solution.
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Fig. 1. Dissolution profiles of the press-coated
STS table in dissolution media of 0.1 mol L–1
HCl and pH 6.8 phosphate buffers. Each point
represents the mean of three determinations.
Photographic study
Visual changes of STS tablets press-coated with PEG 6000-Eudragit S100 blends (2:1,
m/m), 150 mg, are shown in Fig. 2. Very clear correlation between rupturing time and
drug release onset was found by visual observation of the tablet during its release. The
photographs were taken at recorded time intervals in order to reveal the changes of the
outer layer during the drug release. It is clear that the tablet remained intact and smooth
in 0.1 mol L–1 HCl for the first 2 h (Fig. 2a) because the dissolution medium did not pen-
etrate into the PEG 6000-Eudragit S100 coating. Thus, after the contact of the outer layer
with the pH 6.8 phosphate buffer solution, the surface of the tablet appeared rough due
to hydration and swelling after 3 h (Fig. 2b) and drug release increased. The first small
crack on the surface of the outer layer was observed after 4 h (Fig. 2c). At the same time,
the released amount of the drug started to increase. After pH 6.8 phosphate buffer had
penetrated into the outer layer, the crack spread in the outer layer after 5 h and approxi-
mately 40 % of the drug was released (Fig. 2d). The outer layer was disintegrated and in-
ternal STS tablet was visible. After 6 h, in the pH 6.8 phosphate buffer solution (Fig. 2e),
STS was partly exposed to the dissolution medium leading to 60 % drug release. This en-
abled subsequent complete release of the drug.
In vivo gamma scintigraphic studies
Press-coated tablets of STS were administered to two men to examine acid resistan-
ce and delayed-release performance of STS in the gastrointestinal tract. Gamma scinti-
graphy of the optimized formulation was performed in healthy human volunteers in or-
der to assess the in vivo drug release behavior.
Gamma scintigraphy is currently considered to be the non-invasive technique of
choice for determining the in vivo performance of dosage forms (4). Gamma scintigra-
phic images of volunteers 1 and 2 are shown in Fig. 3a,b. The discrete bright spots re-
corded in sequential images indicated that the tracer incorporated in the active core was
not released during the first five hours after administration. Acid resistance of the outer
barrier layer of the press-coated tablets protected the drug in the active core from the
acid environment during the gastric residence period. After 5 hours of administration,
the tablets began to release the tracer, suggesting that the press-coated layer began to
play its delayed-release function. The tablets were disintegrated after 7 h, as evident
from the distribution of the tracer in the different parts of the colon shown in Fig. 3.
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Fig. 2. Morphological changes of the press-coated tablet at various time intervals during dissolution
testing: a) 2 h, b) 3 h, c) 4 h, d) 5 h and e) 6 h.
CONCLUSIONS
Delayed release tablets with salbutamol sulfate as a core and homogenous blend of
PEG 6000 and Eudragit S100 as outer barrier layer were developed. The press-coated
salbutamol sulfate tablet can produce a successful drug release for a programmable pe-
riod of time based on release in vitro as well as in vivo gamma scintigraphic study.
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Fig. 3. Gamma scintigraphic images of the press-coated tablet at different time intervals: a) volun-
teer 1 and b) volunteer 2.
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